Allergic Rhinitis Global Market Report 2024

The global allergic rhinitis market has grown steadily in recent years. It will grow from $14.57 billion in 2023 to $15.22 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to allergen exposure, environmental changes, public awareness, incresing pollution, research and developments on allergic rhinitis, rising disposable incomes.

The global allergic rhinitis market is expected to see steady growth in the next few years. It will grow to $17.62 billion in 2028 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to demand for preventive treatments, aging population, urbanization, health care spending. Major trends in the forecast period include biologics and monoclonal antibodies, digital health solutions, allergen avoidance strategies, pediatric allergic rhinitis, allergen detection technology.

The growth in the allergic rhinitis market is being fueled by elevated levels of air pollution and the effects of climate change. Air pollution, which involves the presence of harmful substances in the Earth's atmosphere, poses a significant risk to both human health and the environment. Climate change, characterized by long-term shifts in climate patterns, further exacerbates this issue. Notably, air pollution has been increasingly recognized for its role in contributing to the prevalence and worsening of allergic rhinitis, underscoring the intricate connection between air quality and respiratory well-being. For instance, in September 2022, the World Bank estimated that the health damage caused by air pollution would result in annual costs of approximately $8.1 trillion, equivalent to 6.1% of the global GDP. Consequently, the high levels of air pollution and the impact of climate change are driving the growth of the allergic rhinitis market.

The growing adoption of corticosteroid treatment in the management of allergic rhinitis is anticipated to be a key driver for the expansion of the allergic rhinitis market. Corticosteroid treatment, commonly known as steroid treatment, encompasses the use of medications called corticosteroids, which have proven effective in reducing inflammation in the nasal passages and alleviating symptoms associated with this condition. For instance, in April 2022 by JAMA Network, a publication by the American Medical Association based in the United States, there has been an upward trend in the utilization of corticosteroids. Their usage has increased significantly, rising from 2.2% in April 2020 to 21.1% in August 2021 for Medicare, and from 2.2% to 13.8% in July 2021 for Sentinel. Consequently, the surge in corticosteroid treatment for allergic rhinitis is a driving force behind the growth of the allergic rhinitis market.

The presence of side effects related to therapies for allergic rhinitis stands as a major impediment to the expansion of the market. Commonly observed adverse effects in the treatment of allergic rhinitis encompass nosebleeds, debilitating headaches, discomfort in the eyes and nose, urinary flow issues in men, and elevated blood pressure in individuals with hypertension. This situation is exacerbated by the increasing trend of self-medication without professional medical guidance. For example, in July 2023, according to a study conducted by the National Library of Medicine, a US-based medical library, challenges in managing airway compromise associated with allergic rhinitis revealed that 27% of patients using first-generation antihistamines experienced sedation, in contrast to 5% of patients using second-generation antihistamines. Hence, the adverse effects linked to allergic rhinitis treatments represent a significant constraint on the growth of the allergic rhinitis market.

Prominent players within the allergic rhinitis market are actively engaged in the development of cutting-edge medications to maintain their market presence. For instance, in August 2022, Hikma Pharmaceuticals PLC, a pharmaceutical company based in the UK, and Glenmark Specialty S.A., a pharmaceutical company headquartered in Switzerland, received approval from the United States Food and Drug Administration (FDA), a federal agency based in the US, for their product known as Ryaltris. Ryaltris represents the first fixed-dose combination medication designed to alleviate both nasal and ocular symptoms of seasonal allergic rhinitis. It is conveniently administered as a nasal spray for adult and pediatric patients aged 12 and above. Notably, the relief from nasal symptoms begins within 15 minutes of the initial dose.

In January 2022, Glenmark Specialty S.A., a pharmaceutical company headquartered in Switzerland, established a partnership with Lotus International Pte. Ltd., a pharmaceutical company based in Singapore. Through this collaboration, Glenmark is set to introduce Ryaltris, an innovative nasal spray designed for allergic rhinitis treatment, into the markets of Singapore, Hong Kong, and Vietnam. Under this arrangement, Glenmark will be responsible for the manufacturing and supply of Ryaltris, while Lotus will oversee the commercialization of Ryaltris in these regions.

Major players in the allergic rhinitis market are Merck and Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., AstraZeneca PLC, GlaxoSmithKline plc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical Industries Limited, Menarini Group, Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Cipla Limited, Endo Pharmaceuticals Inc., Zydus Lifesciences Ltd., Lupin Limited, Glenmark Pharma Ltd., Almirall S.A., Kyowa Kirin Co. Ltd., Hanmi Pharmaceutical Co. Ltd., Akorn Inc.

North America was the largest region in the allergic rhinitis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in allergic rhinitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the allergic rhinitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Allergic rhinitis can be categorized into several types, including seasonal allergic rhinitis (SAR), perennial allergic rhinitis, and occupational allergic rhinitis. SAR is characterized by the rapid onset and resolution of symptoms, often associated with allergens like pollen. The treatments for allergic rhinitis encompass various options such as antihistamines, corticosteroids, immunotherapy, and decongestants. Diagnosis and evaluation may involve different tests like skin tests, IgE radioallergosorbent tests, and complete blood counts. These treatments are administered through various routes, including oral and nasal administration. Moreover, they are accessible through diverse distribution channels such as hospital pharmacies, retail pharmacies, and online stores.

This report provides allergic rhinitis market statistics, including allergic rhinitis industry global market size, regional shares, competitors with an allergic rhinitis market share, detailed allergic rhinitis market segments, market trends and opportunities and any further data you may need to thrive in the allergic rhinitis industry. This allergic rhinitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The allergic rhinitis market consists of revenues earned by entities by providing treatments such as alternative therapies, surgeries and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The allergic rhinitis market also includes sales of allergy pills and injections that are used for the treatment of the disease. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.